AR087640A1 - Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma - Google Patents

Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma

Info

Publication number
AR087640A1
AR087640A1 ARP120103098A ARP120103098A AR087640A1 AR 087640 A1 AR087640 A1 AR 087640A1 AR P120103098 A ARP120103098 A AR P120103098A AR P120103098 A ARP120103098 A AR P120103098A AR 087640 A1 AR087640 A1 AR 087640A1
Authority
AR
Argentina
Prior art keywords
protein
tetranectina
apolipoproteina
same
particle containing
Prior art date
Application number
ARP120103098A
Other languages
English (en)
Inventor
Schantz Christian
Bader Martin
Falkenstein Roberto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR087640A1 publication Critical patent/AR087640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)

Abstract

Aquí se describe una proteína de fusión tetranectina-apolipoproteína A-I acortada y una partícula lipídica que comprende la proteína de fusión tetranectina-apolipoproteína A-I acortada así como la utilización de las mismas. Reivindicación 1: Una proteína de fusión que posee la secuencia de aminoácidos del ID. de Sec. Nº 01 o es una variante de la misma que posee al menos un 70 % de identidad de secuencia con la secuencia de aminoácidos de ID. de Sec. Nº 01.
ARP120103098A 2011-08-25 2012-08-23 Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma AR087640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11178746 2011-08-25

Publications (1)

Publication Number Publication Date
AR087640A1 true AR087640A1 (es) 2014-04-09

Family

ID=46704687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103098A AR087640A1 (es) 2011-08-25 2012-08-23 Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma

Country Status (11)

Country Link
US (2) US8791063B2 (es)
EP (1) EP2748191A1 (es)
JP (2) JP6207507B2 (es)
KR (1) KR20140054115A (es)
CN (1) CN103703023A (es)
AR (1) AR087640A1 (es)
BR (1) BR112013033562A2 (es)
CA (1) CA2838070A1 (es)
MX (1) MX2014001920A (es)
RU (1) RU2014108240A (es)
WO (1) WO2013026860A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124558B2 (en) * 2017-06-02 2021-09-21 The Feinstein Institutes For Medical Research Use of tetranectin and peptide agonists to treat inflammatory diseases

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
WO1992005192A1 (en) 1990-09-18 1992-04-02 Biotech Australia Pty. Limited T-cell epitopes
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
EP1276754A4 (en) 2000-04-14 2005-04-06 Nuvelo Inc MATERIALS AND METHODS RELATING TO LIPID METABOLISM
CA2428114C (en) * 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
IL165253A0 (en) 2002-05-17 2005-12-18 Esperion Therapeutics Inc Methods and compositions for the treatment of ischemic reperfusion
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
ITMI20021058A1 (it) 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
AU2003239777A1 (en) * 2002-07-05 2004-01-23 Borean Pharma A/S Multimerised growth hormone fusion proteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20040180445A1 (en) 2003-03-12 2004-09-16 Domanico Michael J. Methods and compositions for purification of nucleic acid from a host cell
EP1486571B1 (en) 2003-06-12 2005-12-14 F. Hoffmann-La Roche Ag Method for the recombinant production of polypeptides
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005041886A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Methods for generating or increasing revenues related to pain inhibitor commerce
CN1901935A (zh) 2003-12-30 2007-01-24 惠氏公司 具有改进耐受性的免疫原组合物中的疏水性蛋白调配物
US20060019870A1 (en) 2004-01-28 2006-01-26 O'donnell Francis E Jr Apoprotein cochleate compositions
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20090143276A1 (en) * 2007-10-08 2009-06-04 Anaphore, Inc. Trimeric IL-1Ra
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US20060110788A1 (en) 2004-10-01 2006-05-25 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
US20060214104A1 (en) 2004-10-26 2006-09-28 Invitrogen Corporation Compositions and methods for analyzing biomolecules using mass spectroscopy
WO2006069371A1 (en) 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006125304A1 (en) 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
US20080248565A1 (en) 2007-03-01 2008-10-09 Invitrogen Corporation Isolated phospholipid-protein particles
US20070254832A1 (en) 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007137400A1 (en) 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
WO2008013885A2 (en) 2006-07-25 2008-01-31 Stratagene California Zwitterionic detergents for the storage and use of dna polymerases
US9637753B2 (en) 2006-08-10 2017-05-02 Plantechno S.R.L. In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins
WO2008094905A2 (en) 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
FR2915490B1 (fr) 2007-04-26 2011-10-28 Univ Joseph Fourier Grenoble I Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
US20110046056A1 (en) 2007-06-20 2011-02-24 Elisabetta Bianchi Apoa-1 peptide mimetics
US20110178029A1 (en) 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
JP2010539995A (ja) * 2007-10-08 2010-12-24 アナフォア インコーポレイテッド 三量体ＩＬ−１Ｒａ
US8999320B2 (en) 2008-01-30 2015-04-07 The Rockefeller University Nanoscale bound bilayers, methods of use and production
AU2009238607B2 (en) 2008-04-25 2015-08-06 Northwestern University Nanostructures suitable for sequestering cholesterol
US20110293557A1 (en) * 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CA2788223A1 (en) 2009-01-23 2010-07-29 Institut De Cardiologie De Montreal Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
KR101584414B1 (ko) 2010-08-30 2016-01-13 에프. 호프만-라 로슈 아게 알칼리 공급원
BR112013004395A2 (pt) 2010-08-30 2019-09-24 Hoffmann La Roche tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização
US20120190609A1 (en) 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
CN103025875A (zh) 2010-08-30 2013-04-03 霍夫曼-拉罗奇有限公司 原核表达构建体
EP2748178B1 (en) 2011-08-25 2018-10-31 F. Hoffmann-La Roche AG Cation and anion exchange chromatography method
KR20140135716A (ko) 2012-02-29 2014-11-26 에프. 호프만-라 로슈 아게 1→2 해독 프레임 이동의 감소 방법
RU2014138583A (ru) 2012-02-29 2016-04-20 Ф. Хоффманн-Ля Рош Аг Способ уменьшения 1- сдвига рамки считывания
CA2862820A1 (en) 2012-02-29 2013-09-06 F. Hoffmann-La Roche Ag On-column enzymatic cleavage

Also Published As

Publication number Publication date
JP2017171670A (ja) 2017-09-28
MX2014001920A (es) 2014-04-14
JP2014529602A (ja) 2014-11-13
CA2838070A1 (en) 2013-02-28
KR20140054115A (ko) 2014-05-08
US9139640B2 (en) 2015-09-22
CN103703023A (zh) 2014-04-02
JP6207507B2 (ja) 2017-10-04
US20130231273A1 (en) 2013-09-05
RU2014108240A (ru) 2015-09-27
US20150011459A1 (en) 2015-01-08
EP2748191A1 (en) 2014-07-02
WO2013026860A1 (en) 2013-02-28
BR112013033562A2 (pt) 2017-02-14
US8791063B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
BR112018012707A2 (pt) inibidores da interação de menin-mll
UY36021A (es) Proteìnas fc multimèricas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
EA201690898A1 (ru) Способы лечения таупатии
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
CL2013000201A1 (es) Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
AR092879A1 (es) Proteinas de fusion de g3p como agentes de union a amiloide
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
UY35745A (es) Derivados sustituidos de fenilalanina
EA201791716A1 (ru) Фармацевтический состав
UY34268A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta
BR112016012002A2 (pt) Vitanolídeos úteis para o tratamento de doenças neurodegenerativas
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
AR076892A1 (es) Conjugados de albumina-peptido amiloide y usos de los mismos
AR087640A1 (es) Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma
PE20160848A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2019007608A (es) Composicion liquida de fibrinogeno humano.
UY34267A (es) Métodos para aumentar el contenido de proteínas,aceites y/o aminoácidos en una planta

Legal Events

Date Code Title Description
FA Abandonment or withdrawal